The article reports on the new approach adopted by the Ontario Public Drug Program (OPDP) related to drug purchases for its formulary. OPDP has invited drug manufacturers to submit proposals for government contracts, that will be evaluated on the based of the amount of discounts offered and the...
High resource beneficiaries of the Ontario drug benefit (ODB) formularyCamacho, XGomes, TJuurlink, DPaterson, MDhalla, IMamdani, M
CA2 THE USE OF RESEARCH ABSTRACTS IN FORMULARY DECISION MAKING BYTHE ONTARIO CANCER DRUG APPROVAL COMMITTEEdoi:10.1016/S1098-3015(10)70026-7A WeizmanC BellElsevier Inc.Value in Health
Purpose: High-strength opioid formulations were delisted (removed) from Ontario's public drug formulary in January 2017, except for palliative patients. We evaluated the impact of this policy on opioid utilization and dosing.Martins, DianaKhuu, WayneTadrous, MinaJuurlink, David N.Mamdani, Muhammad...
Drug Formulary. Available online:https://www.cancercareontario.ca/en/drugformulary/regimens(accessed on 4 October 2022). Tang, C.; Kuruvilla, J. Optimal Frontline Management of Mantle Cell Lymphoma: Can We Agree?Expert. Rev. Hematol.2018,11, 911–914. [Google Scholar] [CrossRef] [PubMed]...
Impact of formulary policy on thiazolidinedione (TZD) use in the ontario drug benefit (ODB) programClinical Pharmacology & Therapeutics, the most cited journal publishing primary investigation in pharmacology and pharmacy, is the authoritative, cross-disciplinary journal in experimental and clinical ...